Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Dang, Vica ^a,b   Jamieson, Frances B ^a,c   Wilson, Sarah ^a,b   Rawte, Prasad ^a   Crowcroft, Natasha S ^a,b,c   Johnson, Karen ^a   Tsang, Raymond S W ^d   Deeks, Shelley L ^a,b  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Canada; Epidemiology; Invasive meningococcal disease; Neisseria meningitidis; Ontario; Serogroup B; Surveillance

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANADA; CASE FATALITY RATIO; CHILD; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; INCIDENCE; INFANT; INVASIVE MENINGOCOCCAL DISEASE; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEWBORN; NUMBERS NEEDED TO TREAT; PRESCHOOL CHILD; SCHOOL CHILD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, MENINGOCOCCAL; MIDDLE AGED; NEISSERIA MENINGITIDIS, SEROGROUP B; ONTARIO; YOUNG ADULT;

EID: 84865418114     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-202     Document Type: Article

References (15)

1. Brown EM, Fisman DN, Drews S, Doman S, Rawte P, Brown S, Jamieson F. Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006. Antimicrob Agents Chemother 2010, 54(3):1016-21. 10.1128/AAC.01077-09, 2826021, 20086160.
2. Tsang RSW, Squires SG, Tam TWS. Characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease cases in Canada in 2001. Can J Microbiol 2003, 49:633-8. 10.1139/w03-074, 14663497.
3. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001, 344:1378-88. 10.1056/NEJM200105033441807, 11333996.
4. Navarro C, Deeks SL, Medaglia A, Tsang RSW. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 Dec, 2005. Can Commun Dis Rep 2007, 33(10):1-15.
5. Public Health Agency of Canada Guidelines for the Prevention and Control of Meningococcal Disease. Can Commun Dis Rep 2005, 31(S1):1-20. Public Health Agency of Canada.
6. Vedros NA. Development of meningococcal serogroups. In Evolution of Meningococcal Disease. Volume 2 1987, 33-7. Boca Raton, Florida: CRC Press.
7. Law DKS, Lorange M, Ringuette L, Dion R, Giguere M, Henderson AM, Stoltz J, Zollinger WD, De Wals P, Tsang RSW. Invasive meningococcal disease in Québec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 2006, 44(8):2743-9. 10.1128/JCM.00601-06, 1594649, 16891487.
8. National Advisory Committee on Immunization (NACI) An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2009, 35(ACS-3):1-40. National Advisory Committee on Immunization (NACI).
9. Perrett KR, Pollard AJ. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 2005, 5(12):1611-25. 10.1517/14712598.5.12.1611, 16318425.
10. Wenger JD, Serogroup B. meningococcal disease: new outbreaks, new strategies. JAMA 1999, 281(16):1541-3. 10.1001/jama.281.16.1541, 10227326.
11. Association of Public Health Epidemiologists in Ontario 10 Integrated Public Health Information System (iPHIS) [http://www.apheo.ca/index.php?pid=187], Association of Public Health Epidemiologists in Ontario.
12. Ministry of Health & Long-Term Care Appendix B: Provincial Case Definitions for Reportable Disease: Meningococcal disease, invasive 2009, Ontario Public Health Standards: Infectious Diseases Protocol, [http://www.health.gov.on.ca/english/providers/program/pubhealth/oph_standards/ophs/infdispro.html], Ministry of Health & Long-Term Care.
13. Ontario Ministry of Health & Long-Term Care Appendix 2: iPHIS Manual 2005, Toronto: Public Health Division, Ontario Ministry of Health & Long-Term Care.
14. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988, 318:1728-33. 10.1056/NEJM198806303182605, 3374545.
15. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules. JAMA 2012, 306(6):573-82.